1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Terumo Corporation
  6. Summary
    4543   JP3546800008

TERUMO CORPORATION

(4543)
  Report
Delayed Japan Exchange  -  12:09 2022-07-07 am EDT
4212.00 JPY   +2.76%
07/06Japanese shares track Wall Street higher, tech stocks lead gains
RE
07/05Orchestra BioMed, Inc. announced that it has received $110.000003 million in funding from Medtronic plc, RTW Investments, LP, SternAegis Ventures, Terumo Corporation, Perceptive Advisors LLC, and other investors
CI
07/04TERUMO : Aortic Announces First Commercial Implant of the Thoraflex Hybrid Device in the United States
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
07/01/2022 07/04/2022 07/05/2022 07/06/2022 07/07/2022 Date
4013(c) 4062(c) 4100(c) 4099(c) 4212 Last
1 624 400 1 034 600 1 271 500 1 706 500 1 350 500 Volume
-1.83% +1.22% +0.94% -0.02% +2.76% Change
More quotes
Estimated financial data (e)
Sales 2023 774 B 5 701 M 5 701 M
Net income 2023 102 B 750 M 750 M
Net cash position 2023 19 453 M 143 M 143 M
P/E ratio 2023 30,2x
Yield 2023 0,90%
Sales 2024 829 B 6 108 M 6 108 M
Net income 2024 117 B 864 M 864 M
Net cash position 2024 82 714 M 609 M 609 M
P/E ratio 2024 26,1x
Yield 2024 0,98%
Capitalization 3 100 B 22 832 M 22 832 M
EV / Sales 2023 3,98x
EV / Sales 2024 3,64x
Nbr of Employees 28 294
Free-Float 95,3%
More Financials
Company
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows: - cardiac surgery devices (53.5%); - medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.; - sanguine transfusion equipments... 
More about the company
Ratings of Terumo Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about TERUMO CORPORATION
07/06Japanese shares track Wall Street higher, tech stocks lead gains
RE
07/05Orchestra BioMed, Inc. announced that it has received $110.000003 million in funding fr..
CI
07/04TERUMO : Aortic Announces First Commercial Implant of the Thoraflex Hybrid Device in the U..
PU
07/04TERUMO : Notification Regarding Status of Acquisition of the Company's Own Shares
PU
07/04Tranche Update on Terumo Corporation's Equity Buyback Plan announced on May 12, 2022.
CI
06/28Terumo Blood and Cell Technologies and GenCure collaborate to advance cell and gene the..
AQ
06/23TERUMO : Plasma Innovation Business Seminar (PDF 3.62 MB)
PU
06/22TERUMO : Announces Voting Results for the Election of Directors (PDF 90.72 KB)
PU
06/17TERUMO : NHS England Chooses Spectra Optia® Apheresis System as Part of MedTech Funding Ma..
PU
06/16NHS England chooses Spectra Optia(R) Apheresis System as part of MedTech Funding Mandat..
AQ
06/15TERUMO : Holmium-166 SIRT Demonstrates Safety and Efficacy in the Treatment of Hepatocellu..
PU
06/06TERUMO : Appoints Three Associates as the Newest Terumo Fellow
PU
06/03TERUMO : Radboudumc and Terumo Europe N.V. Sign Collaboration Agreement
PU
06/02TERUMO : Notification Regarding Status of Acquisition of the Company's Own Shares (PDF 103..
PU
06/02Diabeloop SAS announced that it has received €70 million in funding from a group o..
CI
More news
News in other languages on TERUMO CORPORATION
05/16Terumo annonce un changement d'indication pour le système CGM Dexcom G6 au Japon
05/13Terumo déclare un dividende plus élevé alors que le bénéfice attribuable de l'exercice ..
05/12TERUMO CORPORATION (TSE : 4543) annonce un rachat d'actions pour 15.000.000 d'actions, rep..
05/12Terumo Corporation fournit des prévisions de dividendes pour l'exercice complet se term..
05/12Terumo Corporation fournit des prévisions de bénéfices consolidés pour l'exercice fisca..
More news
Analyst Recommendations on TERUMO CORPORATION
More recommendations
Stock Trading Strategies
TERUMO CORPORATION - 2021
Big comeback of buyers
BUY
More Stock Trading Analysis
Chart TERUMO CORPORATION
Duration : Period :
Terumo Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TERUMO CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 4 099,00 JPY
Average target price 5 037,14 JPY
Spread / Average Target 22,9%
EPS Revisions
Managers and Directors
Shinjiro Sato Senior Executive Officer
Naoki Muto Chief Financial & Accounting Officer
Toshiaki Takagi Chairman
Katsuya Takeuchi Chief Information Officer & Executive Officer
Kazuhisa Senshu Chief Clinical & Regulatory Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
TERUMO CORPORATION-15.64%22 841
ABBOTT LABORATORIES-22.77%191 378
MEDTRONIC PLC-13.37%120 235
BECTON, DICKINSON AND COMPANY0.21%70 676
BAXTER INTERNATIONAL INC.-24.15%32 926
HOYA CORPORATION-31.18%31 359